CHAMPAIGN, Ill. — Researchers at the University of Illinois Urbana-Champaign report that a precision gene-editing strategy can reduce the toxic protein burden and neurological symptoms of Huntington’s disease in mice. Instead of silencing the HTT gene, the approach reframes treatment as a controlled modification of how the mutant protein is processed inside cells.
Huntington’s disease is driven by a mutation in the HTT gene that makes the huntingtin protein susceptible to cleavage into fragments that accumulate and harm neurons. Because disease onset often occurs in midlife, many people first recognize their condition only after years of biological change, underscoring the need for interventions that can alter disease progression.
The Illinois team employed CRISPR base editing, a DNA-writing method designed to chemically convert one nucleotide to another without creating double-strand breaks. Their base editor targets a specific region within HTT that, when cleaved, helps initiate the cascade leading to the most damaging fragments. By redirecting this processing step, the edited cells avoid producing key toxic species while preserving enough normal huntingtin function for basic biology.
To identify candidates suitable for in vivo use, the researchers screened more than 140 base editors. They selected variants demonstrating the best balance of efficiency and minimal unintended effects, then delivered the most promising editors into the brains of mice carrying mutant HTT genes.
Treated animals showed lower accumulation of toxic huntingtin fragments compared with untreated controls. Behavioral and neurological assessments indicated reduced disease-associated symptoms, alongside less brain degeneration over the study period. The findings collectively support the feasibility of a “processing correction” paradigm for genetic disorders.
Lead investigator Pablo Perez-Pinera emphasized that this work highlights a new way to think about Huntington’s therapy: a small genetic edit can shift protein maturation rather than fully inactivating a gene or broadly disrupting parallel pathways. Thomas Gaj added that the strategy illustrates how modifying protein function through targeted reading changes may be sufficient to limit damage.
The study also suggests a broader platform: base editors may be repurposed to mitigate other genetic diseases by tuning how transcripts are interpreted or how proteins are generated. The work therefore extends the conceptual toolkit beyond one-to-one mutation correction.
Next, the team plans to improve delivery to the brain to reduce invasiveness and minimize reliance on viral transport. Graduate student Kyrollos Shenouda noted that the group is also exploring additional HTT targeting sites to suppress other toxic aspects of the mutant protein.
Subject of Research: Animals
Article Title: In vivo CRISPR base editing for treatment of Huntington’s disease
News Publication Date: 29-Jul-2026
Web References: http://dx.doi.org/10.1038/s41551-026-01747-y
References: Nature Biomedical Engineering; “In vivo CRISPR base editing for treatment of Huntington’s disease” (DOI: 10.1038/s41551-026-01747-y)
Image Credits: Craig Pessman
Keywords
CRISPR base editing; Huntington’s disease; HTT; gene therapy; in vivo brain delivery; neurodegeneration; toxic protein fragments; Nature Biomedical Engineering
Tags: advanced gene editing strategies for neurodegenerative diseasesCRISPR base editing in neurodegenerative diseasesCRISPR-based treatment for Huntington’s diseasegene therapy to prevent neuronal damageHuntington’s disease gene editingin vivo gene therapy for neurological disordersmutant huntingtin protein modificationmutation correction in Huntington’s disease mouse modelsprecision genome editing for neurodegenerationreducing neurotoxicity through DNA base editingtargeted DNA editing to reduce toxic protein accumulationtherapeutic genome editing for late
